The Cohort Study of Uveitis Patients

Uveitis Clinical Trial

Official title:

The Cohort Study of Uveitis Patients Based on Real-world Data

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05727540
• Other study ID #: IIT2022146
• Status: Recruiting
• Start date: February 20, 2023
• Est. completion date: March 31, 2026

Study information

• Verified date: January 2023
• Source: Zhongshan Ophthalmic Center, Sun Yat-sen University
• Contact: Ye Dai, doctor
• Phone: 13512721192
• Email: daiye[@]gzzoc.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study intends to explore the epidemiology, pathogenesis, clinical manifestations, diagnosis and treatment of uveitis. This is a cohort study. The outcome of the study is the activity of inflammation and visual prognosis. The purpose of this study is to determine the optimal diagnosis and treatment scheme for uveitis patients based on real-world data.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 600
• Est. completion date: March 31, 2026
• Est. primary completion date: February 20, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• The diagnosis is uveitis; The agreement of enrolling this study;

Exclusion Criteria:

• Uveitis during the first month after any intraocular surgery; <18 years; pregnant and lactating women; other conditions are unsuitable for participation in this study by the investigator such as mental abnormalities.

Related Conditions & MeSH terms

• Uveitis

Locations

Country	Name	City	State
China	Zhongshan Ophthalmic Center	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Zhongshan Ophthalmic Center, Sun Yat-sen University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The socre of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system	activity of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system	12 months post-treatment
Primary	The range of inflammatory chorioretinal and/or inflammatory retinal vascular lesions	inflammatory chorioretinal and/or inflammatory retinal vascular lesions were evaluated by fundus fluorescein angiography and indocyanine green angiography	12 months post-treatment
Secondary	Best corrected visual acuity	Best corrected visual acuity	1 month post-treatment
Secondary	Best corrected visual acuity	Best corrected visual acuity	3 months post-treatment
Secondary	Best corrected visual acuity	Best corrected visual acuity	6 months post-treatment
Secondary	Best corrected visual acuity	Best corrected visual acuity	12 months post-treatment
Secondary	Best corrected visual acuity	Best corrected visual acuity	24 months post-treatment
Secondary	Best corrected visual acuity	Best corrected visual acuity	36 months post-treatment
Secondary	The number of intraocular pressure	The number of Intraocular pressure was examed by non-contact tonometer	1 month post-treatment
Secondary	The number of intraocular pressure	The number of Intraocular pressure was examed by non-contact tonometer	3 months post-treatment
Secondary	The number of intraocular pressure	The number of Intraocular pressure was examed by non-contact tonometer	6 months post-treatment
Secondary	The number of Intraocular pressure	The number of Intraocular pressure was examed by non-contact tonometer	12 months post-treatment
Secondary	The number of Intraocular pressure	The number of Intraocular pressure was examed by non-contact tonometer	24 months post-treatment
Secondary	The number of Intraocular pressure	The number of Intraocular pressure was examed by non-contact tonometer	36 months post-treatment
Secondary	Central retinal thickness	Central retinal thickness was evaluated by Optical Coherence Tomography	1 month post-treatment
Secondary	Central retinal thickness	Central retinal thickness was evaluated by Optical Coherence Tomography	3 months post-treatment
Secondary	Central retinal thickness	Central retinal thickness was evaluated by Optical Coherence Tomography	6 months post-treatment
Secondary	Central retinal thickness	Central retinal thickness was evaluated by Optical Coherence Tomography	12 months post-treatment
Secondary	Central retinal thickness	Central retinal thickness was evaluated by Optical Coherence Tomography	24 months post-treatment
Secondary	Central retinal thickness	Central retinal thickness was evaluated by Optical Coherence Tomography	36 months post-treatment
Secondary	The socre of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system	activity of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system	1 month post-treatment
Secondary	The socre of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system	activity of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system	3 months post-treatment
Secondary	The socre of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system	activity of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system	6 months post-treatment
Secondary	The socre of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system	activity of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system	24 months post-treatment
Secondary	The socre of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system	activity of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system	36 months post-treatment
Secondary	The range of inflammatory chorioretinal and/or inflammatory retinal vascular lesions	inflammatory chorioretinal and/or inflammatory retinal vascular lesions were evaluated by fundus fluorescein angiography and indocyanine green angiography	3 months post-treatment
Secondary	The range of inflammatory chorioretinal and/or inflammatory retinal vascular lesions	inflammatory chorioretinal and/or inflammatory retinal vascular lesions were evaluated by fundus fluorescein angiography and indocyanine green angiography	6 months post-treatment
Secondary	The range of inflammatory chorioretinal and/or inflammatory retinal vascular lesions	inflammatory chorioretinal and/or inflammatory retinal vascular lesions were evaluated by fundus fluorescein angiography and indocyanine green angiography	24 months post-treatment
Secondary	The range of inflammatory chorioretinal and/or inflammatory retinal vascular lesions	inflammatory chorioretinal and/or inflammatory retinal vascular lesions were evaluated by fundus fluorescein angiography and indocyanine green angiography	36 months post-treatment